AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Prof Hong talks to ecancertv about the upcoming WIN symposium, which is taking place on the 29 - 30 June in Paris, France.
The symposium provides a chance, he says, to interact with "world class leaders in personalised therapy" and the opportunity to hear the results of the latest personalised cancer care trials.
WIN 2015 hosts 'world class leaders' in personalised therapy
Prof Waun Ki Hong - University of Texas MD Anderson Cancer Center, Houston, USA
Number one is the opportunity to learn about the WIN Consortium’s mission and number two is a tremendous opportunity to meet, to interact with really world class leaders in personalised cancer therapy. The other reason is the opportunity to hear about really cutting edge, state of the art, personalised cancer therapy trials, the results. Also this is a tremendous opportunity for individual persons to present their own data of personalised cancer therapy through the WIN Consortium Symposium.
I think, again, this is a unique opportunity. People who are interested to learn more about personalised cancer therapy then this is the right meeting. I recommend very strongly to people to attend this wonderful meeting in Paris.
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
ctDNA evaluation may play a prognostic role in stage III colon cancer treated with celecoxib
Revolutionising myeloma treatment through immune profiling
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting